IMMPIMMUTEP Ltd

Nasdaq immutep.com


$ 2.01 $ 0.14 (7.49 %)    

Friday, 28-Jun-2024 15:59:55 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 2.01
$ 1.96
$ 0.00 x 0
$ 0.00 x 0
$ 1.85 - $ 2.02
$ 1.58 - $ 3.34
764,154
na
238.65M
$ 0.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baird-maintains-outperform-on-immutep-lowers-price-target-to-6

Baird analyst Joel Beatty maintains Immutep (NASDAQ:IMMP) with a Outperform and lowers the price target from $7 to $6.

 immutep-and-cardiff-university-sign-exclusive-license-for-next-generation-anti-lag-3-molecules-for-cancer

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...

 reported-earlier-immutep-teams-up-with-msd-to-test-efti-and-keytruda-combination-in-phase-iii-non-small-cell-lung-cancer-trial

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD's anti-PD-1 therapy, and standard chemothera...

 capital-one-initiates-coverage-on-immutep-with-overweight-rating-announces-price-target-of-10

Capital One analyst Naureen Quibria initiates coverage on Immutep (NASDAQ:IMMP) with a Overweight rating and announces Price...

 earlier-immutep--data-from-safety-lead-in-phase-of-aipac-003-confirmed-complete-response-in-a-patient-with-metastatic-breast-cancer-refractory-to-several-lines-of-therapy-achieved-during-combination-treatment-with-90mg-efti-and-paclitaxel

– Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...

 initial-clinical-data-reported-from-immuteps-efti-combined-with-radiotherapy-and-checkpoint-inhibitor-from-phase-ii-trial-in-soft-tissue-sarcoma

Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial e...

 why-australian-cancer-biotech-firm-immutep-stock-is-soaring-on-wednesday

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients...

 immutep-announced-tuesday-data--from-efti-in--combination--with-keytruda-in--first--line-head--and--neck--squamous--cell--carcinoma-patients-who-do-not-express-pd-l1-shows-a-preliminary-269-response-rate-the-primary-endpoint-of-the-study

 Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...

 immutep-appoints-leading-research-institute-to-conduct-first-in-human-phase-i-study-of-imp761

Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody de...

Core News & Articles

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...

 cancer-focused-immuteps-stock-soars-on-tuesday---heres-why

Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic...

 immutep-announces-first-clinical-data-from-90mg-dosing-of-efti

Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEn...

 first-patient-dosed-in-trial-evaluating-efti-and-the-anti-pd-l1-therapy-bavencio-in-metastatic-urothelial-cancer

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...